Research Article

Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis

Figure 3

Cost-effectiveness of rifaximin-α plus lactulose compared with lactulose monotherapy in the second-line setting: (a) cost-effectiveness acceptability curve at a 2-year time horizon; (b) cost-effectiveness plane at a 2-year time horizon; (c) cost-effectiveness acceptability curve at a 5-year time horizon; and (d) cost-effectiveness plane at a 5-year time horizon. In panel (a) and (c), the horizontal axis (cost-effectiveness threshold) displays willingness-to-pay budgetary thresholds to gain one additional QALY when using rifaximin-α plus lactulose in lieu of lactulose. The vertical axis (probability cost-effective) displays the proportion of patients that fall within the budget. In panel (b) and (d) the confidence intervals (CI) define the regions that contain 95% CI (yellow), 75% CI (green), and 50% CI (blue) of the samples that can be drawn from the underlying Gaussian distribution. Abbreviations: CI: confidence interval; QALY: quality-adjusted life-year; US$: United States dollars.
(a)
(b)
(c)
(d)